Latt D, Weiss J B, Jayson M I
Ann Rheum Dis. 1981 Apr;40(2):157-60. doi: 10.1136/ard.40.2.157.
The levels of beta 2-microglobulin (beta 2-m) in serum and urine of 24 seropositive patients with rheumatoid arthritis (RA) treated with regular gold (sodium aurothiomalate) injections have been investigated. The values obtained were compared with levels from 20 seropositive patients with RA treated only with nonsteroidal anti-inflammatory drugs and 20 age and sex matched normal controls who had received no medication. A significant increase of urinary beta 2-m levels was found in the gold-treated RA group. No correlation between dose of gold received and the levels of beta 2-m in the urine could be established. There was also no correlation between the erythrocyte sedimentation rate (ESR) or total lymphocyte count and beta 2-m levels in serum or urine. We conclude that serum and urinary beta 2-m levels appear to be poor indices of joint inflammation, but sequential urinary beta 2-m levels may prove valuable in monitoring the development of renal tubular lesions due to gold therapy.
对24例接受常规金制剂（硫代苹果酸金钠）注射治疗的类风湿关节炎（RA）血清学阳性患者的血清和尿液中的β2-微球蛋白（β2-m）水平进行了研究。将所得值与20例仅接受非甾体抗炎药治疗的RA血清学阳性患者以及20例年龄和性别匹配且未接受任何药物治疗的正常对照者的水平进行比较。在接受金制剂治疗的RA组中，尿β2-m水平显著升高。所接受的金剂量与尿中β2-m水平之间未发现相关性。红细胞沉降率（ESR）或总淋巴细胞计数与血清或尿液中的β2-m水平之间也没有相关性。我们得出结论，血清和尿β2-m水平似乎不是关节炎症的良好指标，但连续的尿β2-m水平可能在监测金制剂治疗引起的肾小管病变发展方面具有价值。
